A-Alpha Bio, a synthetic biology and machine learning company, has announced its collaboration with Gilead that aims to advance the design of human immunodeficiency virus (HIV) therapies.
Vir Biotechnology has been awarded a new $10 million grant by the Bill & Melinda Gates Foundation to support its novel T cell vaccine development program for the prevention of HIV.